Fox Run Management L.L.C. Buys New Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Fox Run Management L.L.C. bought a new stake in Vaxcyte, Inc. (NASDAQ:PCVX) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 3,989 shares of the company’s stock, valued at approximately $327,000.

Several other hedge funds also recently modified their holdings of the company. Janus Henderson Group PLC lifted its stake in shares of Vaxcyte by 23.1% during the third quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company’s stock valued at $1,247,954,000 after buying an additional 2,052,989 shares during the period. RA Capital Management L.P. lifted its stake in shares of Vaxcyte by 5.9% during the 3rd quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company’s stock worth $992,914,000 after purchasing an additional 485,436 shares during the period. Point72 Asset Management L.P. purchased a new position in shares of Vaxcyte during the 3rd quarter worth $41,114,000. Franklin Resources Inc. boosted its holdings in shares of Vaxcyte by 13.2% during the third quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company’s stock worth $315,162,000 after purchasing an additional 324,560 shares during the last quarter. Finally, Maverick Capital Ltd. grew its position in shares of Vaxcyte by 41.9% in the third quarter. Maverick Capital Ltd. now owns 976,249 shares of the company’s stock valued at $111,556,000 after purchasing an additional 288,341 shares during the period. 96.78% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Vaxcyte

In other news, Director Teri Loxam sold 6,250 shares of Vaxcyte stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total transaction of $531,937.50. Following the sale, the director now directly owns 7,175 shares of the company’s stock, valued at approximately $610,664.25. The trade was a 46.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Jim Wassil sold 8,000 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $83.66, for a total value of $669,280.00. Following the transaction, the chief operating officer now owns 205,695 shares of the company’s stock, valued at approximately $17,208,443.70. This trade represents a 3.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 46,250 shares of company stock valued at $3,840,018 over the last quarter. Company insiders own 3.10% of the company’s stock.

Analysts Set New Price Targets

PCVX has been the topic of a number of research analyst reports. The Goldman Sachs Group began coverage on Vaxcyte in a research note on Friday, December 20th. They issued a “buy” rating and a $135.00 price target on the stock. Guggenheim reissued a “buy” rating and issued a $160.00 target price on shares of Vaxcyte in a research report on Wednesday, March 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a research note on Wednesday, February 26th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vaxcyte currently has an average rating of “Buy” and an average target price of $147.50.

Vaxcyte Stock Down 4.6 %

PCVX opened at $68.56 on Thursday. Vaxcyte, Inc. has a 52-week low of $58.10 and a 52-week high of $121.06. The company has a 50 day moving average of $80.72 and a two-hundred day moving average of $93.16. The company has a market cap of $8.83 billion, a P/E ratio of -14.90 and a beta of 1.02.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.14. Research analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.